Candel Therapeutics(CADL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights • Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancer • Presented positive topline overall survival data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • Received orphan drug designation from the U.S. Food an ...